Tags Posts tagged with "Marijuana Stocks to watch in 2017"

Marijuana Stocks to watch in 2017

0 13103

Among the many segments of the marijuana industry that we cover, CBD has taken on a big role not only for its biotech-based applications but also for its uses outside of the health sciences sector. And with the growth that the market as a whole could be set to see, CBD companies are definitely in the spotlight for the foreseeable future.

One Marijuana Stock that we’ve been reporting on since late last year has been Ubiquitech Software Corp (UBQU).  Now don’t let the name fool you, this company, through its subsidiary HempLife Today™ is breaking barriers with its CBD brand while also hitting major milestones over the last year.  What could be best of all is that 2017 could already have the stage set for yet another record setting period in (UBQU)’s company history.

Earlier this morning the company put out preliminary guidance on what it is anticipating to be a banner year ahead.  According to the release, the company anticipates that revenues for the year ending November 30, 2017 will increase over 55% from $3,493,113, which was reported in the annual period ended November 30, 2016 to approximately $5,450,000.

Ubiquitech Gives Fiscal Year 2017 Revenue Guidance; Anticipates 55% Year Over Year Increase To $5,450,000

“We are very pleased with the progress we have made and we will continue to do everything within our power to keep our company relevant and growing” said James Ballas, CEO “With the quality of our products, our marketing, customer support and satisfaction, and our dynamic thinking, we will continue this growth through 2017 and into 2018, which we are already planning big things for, and this is the thinking that will take our revenues to even higher gains as we continue. It’s a very exciting industry and we don’t plan to stop until the CannazALL brand is a household word.”

(UBQU) is no stranger to growth.  If you’re just pulling up the company’s other headlines, you’ll already notice major strides being made on the product end. Toward the beginning of the year, the company announced that it had concluded negotiations and reached an agreement to expand its hemp growing capabilities through an additional 140 acres of available hemp operations. They’ve also expanded their current product line to include brand new offerings.

But back to growth…Had this been a random company with its first press release in history, we might be a bit skeptical but (UBQU) has already proven its ability to run a multi-million dollar business that has managed to grow significantly just within the last year alone. On top of bullish guidance for the year ahead, (UBQU) is also coming off of a strong year and noticeable earnings growth.

Revenues for the last quarter increased to $1,225,015 and to $3,493,113 for the year. But what’s more is that net income increased over 700% from the previous year to $334,350 from $39,651 in 2015. First quarter guidance has already come in bullish on its own with the company expecting revenues for the quarter ended February 28, 2017 to increase over 50% from $697,640 in the first quarter of last year to approximately $1,050,000.

Of course this is just initial guidance and with the year ahead, nothing is set in stone. But one thing is certain and that based on the last releases from the company, (UBQU) has set itself on a growth trend.  So this bullish guidance could be shedding some light on what’s to come for this company in the very near term.

The opportunity for taking advantage of the growth that CBD is beginning to see, could be important to take into consideration.  We’ve previously written about this market and how it could be on a path for growth.  Figures estimate that the CBD market will grow to a $2.1 billion market in sales by 2020. That’s a 700% increase from 2016.  Think about this for a moment: (UBQU) is already growing and is expecting to continue this growth to the tune of 50+% for the year according to today’s announcement…this is all going to happen during a time where the CBD industry as a whole is also anticipating significant growth. Having already come off of a banner year, we think that preliminary guidance from the company would suggest that this is something to be paying close attention to moving into the coming weeks/months/quarters.

Again, you can access today’s (UBQU) news here:

Ubiquitech Gives Fiscal Year 2017 Revenue Guidance; Anticipates 55% Year Over Year Increase To $5,450,000

Pursuant to an agreement between MAPH and Ubiquitech Software Corp., we were hired for a period beginning November 11 2016 and ending May 11, 2017 to publicly disseminate information about (UBQU) including on the Website and other media including Facebook and Twitter. We are being paid $0 (CASH) for or were paid “10 million” shares of restricted common shares. We may buy or sell additional shares of (UBQU) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Full Disclaimer Here

 

 

 

0 1872

DENVER, CO–(Mar 23, 2017) – Ubiquitech Software Corp. ( OTC PINK : UBQU ), through its operating subsidiary HempLifeToday.com, is announcing fiscal year 2017 revenue guidance.

The company anticipates that revenues for the year ending November 30, 2017 will increase over 55% from $3,493,113 reported in the year ago period to approximately $5,450,000.

The company is basing this guidance on the strong internal first quarter numbers and the continuance of that trend during March of this year. The company continues to gain increased exposure of its HempLife Today product line, develop new and improved products, and spread the word regarding the benefits of CBD Hemp derived products available and sold through its proprietary CBD brand CannazALL.

The company expects to give updates on its full year guidance in the coming months. The company sells and markets its line of high quality products through its web portal www.HempLifeToday.com.

“We are very pleased with the progress we have made and we will continue to do everything within our power to keep our company relevant and growing,” said James Ballas, CEO. “With the quality of our products, our marketing, customer support and satisfaction, and our dynamic thinking, we will continue this growth through 2017 and into 2018, which we are already planning big things for, and this is the thinking that will take our revenues to even higher gains as we continue. It’s a very exciting industry and we don’t plan to stop until the CannazALL brand is a household word.”

“With the wide footprint we have on the Internet and the amount of industry content about us that is also growing, we have the ability to grow while also protecting revenue,” adds Tim Zorn, President. “This allows us to strategically spend advertising dollars where we get the best results and is why our cost per customer acquisition is down by over 90% since last year. Steady sales and profitability is what we always strive for.”

The Company wants shareholders to know that it is moving forward on all plans released in previous press from 3.09.2017. This update is to inform shareholders of company progress and to keep shareholders informed of said progress.

About Ubiquitech (HempLife Today™)
Ubiquitech Software Corp, through its subsidiaries is a dynamic multi-media, multi-faceted corporation utilizing state-of-the-art global internet marketing, Direct Response (DRTV) Television, Radio, and traditional marketing, to drive traffic to the new and emerging multi-billion dollar industries like its subsidiary HempLifeToday.com™

HempLifeToday™ focuses on the exciting and dynamic new thinking in the world today that recognizes the important health and life enriching enhancement that CBD Oil from the Hemp plant can bring. Through its network of quality USA growers HempLifeToday.com™ has developed multiple and proprietary CannazALL™ CBD oil products that include; It’s popular CBD Tinctures, Oils, GelCaps, CBD Powder, Skin Salve, Wax Crumble, and e-liquid, all offered @ www.HempLifeToday.com

This press release contains forward-looking statements. Words such as “expects”, “intends”, “believes”, and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company’s filings with the OTC Markets Group. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.

0 5603
Marijuana Stocks

Marijuana Stocks, especially Cannabis Companies with strong ties to Biotech have been increasingly front and center on Wall Street’s main stage.  Marijuana Stocks and the Cannabis-Biotech sector continue to evolve and grow into the mainstream powerhouse we know it can and will be. We have identified a small Cannabis-Biotech start up that deserves your attention.

InMed Pharmaceuticals (IMLFF) is a Vancouver-based pre-clinical trial Cannabis-Biotech company that has not only developed a proprietary cannabinoid manufacturing system yet in the process created a highly sought after database, which has mapped the different compounds of cannabinoids to the various diseases that it can address.

This cannabinoid database was designed by (IMLFF) to assist them in their investigative studies and has currently become a core asset as other Cannabis Biotech companies have come knocking on their door willing to offer a hefty sum for this information. Most medical marijuana processors are using THC and CBD because they are easy to extract in large quantities, however there are more than 90 diverse cannabinoid structures that (IMLFF) has plugged into its system. The bioinformatics algorithm has taken those different compounds and screens them against approved drugs, diseases and genetic properties of diseases. It then selects specific cannabinoids that might help regulate that particular disease.

InMed Pharmaceuticals (IMLFF) has created this database “tool” & is saving time and money in the drug research process. It has already helped (IMLFF) to identify two treatments for rare diseases. One for a rare children’s skin disease called epidermolysis bullosa (EB) that has no approved treatments and the other for glaucoma. Chief Executive Officer Eric Adams said, “It’s a very devastating disease and we found out in early testing that this set of cannabinoids treat the major symptoms of this disease giving them a tremendous amount of relief, but it may also reverse the disease, which is something no one has really talked about before.”

Startup Cannabis-Biotechs like InMed Pharmaceuticals (IMLFF) will continue to grow as Marijuana Stocks / Sector continues to evolve into mainstream markets.

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements